Ribonucleic Acid (RNA) Markers Market, by Type (Prestained Markers, Unstained Markers and Specialty Markers), by Application (Nucleic Acid Applications and Proteomics Applications), by End User (Research Centers, Pharmaceutical and Biotechnology Companies and Others (Academic Institutes, Forensic Laboratory and Others)) by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Mar 2023

Code : CMI5584

Pages :195

Formats :

Excel and PDF

Industry : Biotechnology

Regional Analysis

Global Ribonucleic Acid (RNA) Markers Market- Regional Analysis

Among all regions, North America region is expected to dominate the market over the forecast period. This is attributed due to the North America hold 34.6% market share owing to increasing research and development activities by the market players in the North America region. For instance, in the year 2021, Pfizer Inc., a pharmaceutical and Biotechnology company invested a total of US$ 120 million in four clinical-stage biotech companies, as part of the Pfizer Breakthrough Growth Initiative (PBGI), during the second half of the year 2020. Through PBGI, Pfizer Inc., invested up to US$ 500 million in biotechnology companies, which will provide funding and further access to Pfizer’s scientific expertise, which in turn, will help in the completion of the clinical development programs. Such investments are expected to increase the use of RNA markers and help in the growth of the market over the forecast period.

Europe region is expected to be the second largest region over the forecast period. Due to increasing investment for research and development activities by the market players. For instance, in June 2022, GSK plc, announced an investment of approximately US$ 1.08 million over ten years, in order to accelerate research and development (R&D) activities for infectious diseases that disproportionately impact lower-income countries. This is expected to increase the use of RNA markers for research and development activities. This research will increase production of disruptive vaccines and medicines, for the prevention and treatment of malaria, tuberculosis, HIV, neglected tropical diseases (NTDs), and anti-microbial resistance (AMR).

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa